Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention | Zendy

Lisette Okkels Jensen | Zendy; Per Thayssen | Zendy; Henrik Hansen | Zendy; Evald Høj Christiansen | Zendy; Hans Henrik Tilsted | Zendy; Lars Romer Krusell | Zendy; Anton Boel Villadsen | Zendy; Anders Junker | Zendy; Knud Nørregaard Hansen | Zendy; Anne Kaltoft | Zendy; Michael Mæng | Zendy; Knud Erik Pedersen | Zendy; Steen Dalby Kristensen | Zendy; Hans Erik Bøtker | Zendy; Jan Ravkilde | Zendy; R. Sanchez | Zendy; Jens Aarøe | Zendy; Morten Madsen | Zendy; Henrik Toft Sørensen | Zendy; Leif Thuesen | Zendy; Jens Flensted Lassen | Zendy; Kristian Thygesen | Zendy; Christian Juhl Terkelsen | Zendy; Bjarne Linde Nørgaard | Zendy; Lars Pedersen | Zendy

Open Access

Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention

Author(s) -

Lisette Okkels Jensen,

Per Thayssen,

Henrik Hansen,

Evald Høj Christiansen,

Hans Henrik Tilsted,

Lars Romer Krusell,

Anton Boel Villadsen,

Anders Junker,

Knud Nørregaard Hansen,

Anne Kaltoft,

Michael Mæng,

Knud Erik Pedersen,

Steen Dalby Kristensen,

Hans Erik Bøtker,

Jan Ravkilde,

R. Sanchez,

Jens Aarøe,

Morten Madsen,

Henrik Toft Sørensen,

Leif Thuesen,

Jens Flensted Lassen,

Kristian Thygesen,

Christian Juhl Terkelsen,

Bjarne Linde Nørgaard,

Lars Pedersen

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.063644

Subject(s) - medicine , stent , percutaneous coronary intervention , hazard ratio , everolimus , sirolimus , clinical endpoint , myocardial infarction , surgery , coronary artery disease , randomized controlled trial , cardiology , confidence interval

Among drug-eluting stents released to date, the sirolimus-eluting stent has demonstrated the least amount of late lumen loss, but its efficacy and safety have not been compared head-to-head with the next-generation everolimus-eluting stent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research